What the FDA labels say about taking them together
Disopyramide and insulin glulisine
Insulin glulisine's FDA label of November 25, 2025 names disopyramide in its drug interactions section; the disopyramide label PlainMeds reads does not name insulin glulisine. The insulin glulisine label: “Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline …”
Check it at the source: the disopyramide FDA label on DailyMed (effective August 24, 2026, Pfizer Laboratories Div Pfizer Inc); the insulin glulisine FDA label on DailyMed (effective November 25, 2025).
What does the disopyramide label say about insulin glulisine?
Disopyramide's label (effective August 24, 2026) does not name insulin glulisine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Norpace), Pfizer Laboratories Div Pfizer Inc, effective August 24, 2026 (SPL set e2aa1642-d262-4520-bc6a-9fd3ad795677), via openFDA; the full label on DailyMed
What does the insulin glulisine label say about disopyramide?
Insulin glulisine label, drug interactionsDrugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when APIDRA is coadministered with these drugs.
Source: FDA drug label (Apidra), sanofi-aventis U.S. LLC, effective November 25, 2025 (SPL set e7af6a7a-8046-4fb4-9979-4ec4230b23aa), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Disopyramide | Insulin glulisine | |
|---|---|---|
| Labeled for | n/a | Type 2 diabetes, Type 1 diabetes |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.801 per capsule 100 mg capsule | $8.16 per mL 100 unit/mL vial |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once